Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Long-Term Deferred Tax: 2009-2012

Historic Long-Term Deferred Tax for Northwest Biotherapeutics (NWBO) over the last 4 years, with Dec 2012 value amounting to $87.6 million.

  • Northwest Biotherapeutics' Long-Term Deferred Tax rose 70.20% to $87.6 million in Q4 2012 from the same period last year, while for Dec 2012 it was $87.6 million, marking a year-over-year increase of 70.20%. This contributed to the annual value of $87.6 million for FY2012, which is 70.20% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Long-Term Deferred Tax stood at $87.6 million for FY2012, which was up 70.20% from $51.5 million recorded in FY2011.
  • Northwest Biotherapeutics' 5-year Long-Term Deferred Tax high stood at $87.6 million for FY2012, and its period low was $39.4 million during FY2009.
  • Over the past 3 years, Northwest Biotherapeutics' median Long-Term Deferred Tax value was $51.5 million (recorded in 2011), while the average stood at $61.0 million.
  • Data for Northwest Biotherapeutics' Long-Term Deferred Tax shows a peak YoY surged of 70.20% (in 2012) over the last 5 years.
  • Yearly analysis of 4 years shows Northwest Biotherapeutics' Long-Term Deferred Tax stood at $39.4 million in 2009, then increased by 11.79% to $44.0 million in 2010, then increased by 16.94% to $51.5 million in 2011, then soared by 70.20% to $87.6 million in 2012.